The Cost and Value of Biomedical Innovation: Implications for Health Policy
Past Event
Are New Breakthrough Treatment Worth Their Price? Assessing the Social Costs and Benefits of Biomedical Innovation

Are New Breakthrough Treatment Worth Their Price? Assessing the Social Costs and Benefits of Biomedical Innovation

What Can We Learn from Recent Hepatitis C Treatments? Understanding the Pricing Process and Spending Consequences for Breakthrough Therapies

How Do We Ensure Future Innovation? Financing Breakthrough Therapies
High-cost drugs and devices that address significant unmet medical needs have generated much attention lately. New treatments for many cancers and for infections like Hepatitis C have the potential to increase life expectancy and quality of life for affected patients. Many more such treatments are in development. While a number of important breakthroughs have occurred in the past several decades, the increasing ability to target treatments based on a better understanding of genomics, systems biology, and other biomedical sciences could lead to more technologies with broader effects for targeted populations. Thus, biomedical innovation may have substantial future implications for population health and health care costs.
On October 1, the Engelberg Center for Health Care Reform and the USC Schaeffer Center for Health Policy and Economics hosted a half-day forum to discuss the serious coverage challenges that accompany breakthrough treatments, such as the much-discussed new treatment for Hepatitis C, Sovaldi. Researchers presented economic modeling simulations that illustrate the value and long-term effects of such treatments; and exploring potential policy solutions for financing biomedical innovations.
Agenda
Are New Breakthrough Treatment Worth Their Price? Assessing the Social Costs and Benefits of Biomedical Innovation
Dana Goldman
Nonresident Senior Fellow - Economic Studies, USC-Brookings Schaeffer Initiative for Health Policy
Margaret Anderson
Executive Director - FasterCures
Douglas Dieterich
Professor of Medicine; Director, Continuing Medical Education - Mount Sinai School of Medicine
Thomas Gustafson
Advisor, FDA and Healthcare Practice Group - Arnold & Porter
What Can We Learn from Recent Hepatitis C Treatments? Understanding the Pricing Process and Spending Consequences for Breakthrough Therapies
Darius Lakdawalla
Director of Research - USC Schaeffer Center for Health Policy & Economics
Quintiles Chair in Pharmaceutical Development and Regulatory Innovation - USC School of Pharmacy
Professor - USC Price School of Public Policy
Ryan Clary
Executive Director - National Viral Hepatitis Roundtable
John Milligan
President and Chief Operating Officer - Gilead
Sam Nussbaum
Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc.
Break
Darius Lakdawalla
Director of Research - USC Schaeffer Center for Health Policy & Economics
Quintiles Chair in Pharmaceutical Development and Regulatory Innovation - USC School of Pharmacy
Professor - USC Price School of Public Policy
Ryan Clary
Executive Director - National Viral Hepatitis Roundtable
John Milligan
President and Chief Operating Officer - Gilead
Sam Nussbaum
Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc.
How Do We Ensure Future Innovation? Financing Breakthrough Therapies
Tomas Philipson
Daniel Levin Professor of Public Policy Studies - University of Chicago
Andrew Allison
Principal - Allison Health Care Consulting
Al Engelberg
Trustee - The Engelberg Foundation
Chris Koller
Rhode Island Office of the Health Insurance Commissioner
Closing Remarks
Dana Goldman
Nonresident Senior Fellow - Economic Studies, USC-Brookings Schaeffer Initiative for Health Policy
Welcome
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.